Sermorelin FDA Approved? The Regulatory History

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub, where we translate GLP-1 therapies, longevity peptides, and metabolic science into decisions you can actually use. Explore the full Peptides & GLP-1 library.

The question "is sermorelin FDA approved" has a real answer, and it is not a simple yes or no. Sermorelin has an approval history, a discontinuation, and a present-day path through compounding pharmacies. Sorting those apart is the whole point of this page, followed by the mechanism, safety framing, and the genetics that sit beneath any longevity decision.

The short answer on regulatory status

Sermorelin was originally FDA-approved in 1990, indicated for diagnostic use and for pediatric growth hormone deficiency. That is the yes. The complication is that the branded product was discontinued in 2008, so the historically approved commercial product is no longer on the market. What people access today is a different animal in regulatory terms.

What compounded access means now

With the branded product gone, adults typically obtain sermorelin as a compounded preparation from a licensed 503A pharmacy. Compounded medications are not reviewed under the same FDA manufacturing process as an approved brand drug; they are prepared patient-specifically under a prescription and are overseen by state pharmacy boards. That is why "FDA approved" is not quite the right frame for the sermorelin most people encounter.

The molecule and how it works

Sermorelin is a synthetic 29-amino-acid peptide that reproduces the active portion of human growth hormone-releasing hormone, GHRH 1-29. It signals the pituitary to release growth hormone in a pulsatile, physiological rhythm. It acts on the growth hormone axis and IGF-1 signaling, pathways well characterized in peer-reviewed literature, with effect sizes that vary by indication, amount, individual factors, and adherence.

How to think about safety

Sermorelin carries a documented safety profile in the clinical literature, though common side effects, warnings, and contraindications vary by preparation. Because compounded products depend on the pharmacy, look for licensure and adherence to USP standards for sterility and potency, and discuss your medical history with a prescribing provider before starting.

The genetic pathway context

Regulatory status describes the product; it says nothing about your biology. Variants in FOXO3, IGF1, and KLOTHO shape the growth hormone and IGF-1 signaling that sermorelin acts through. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across that landscape. It never predicts response to any compound; it maps the terrain a clinician is prescribing into. PlexusDx offers sermorelin through its Longevity Protocols, with specifics on the Sermorelin product page.

Why the distinction matters when you are buying

The gap between "FDA approved in 1990" and "compounded today" is not academic, because marketing sometimes blurs it. A seller who implies that compounded sermorelin carries the same approval status as a reviewed brand drug is overstating the case. Compounded preparations are prepared patient-specifically under a prescription and overseen by state pharmacy boards, which is a different framework than brand-drug approval.

For a buyer, the practical takeaways are simple. Verify that a licensed prescriber conducted a real evaluation, that the pharmacy is state-licensed and follows USP standards for sterility and potency, and that the product arrives with proper labeling. Sermorelin has a documented safety profile in the literature, but warnings and contraindications vary by preparation, so the clinical conversation, not a claim of approval, is what should guide the decision.

Reading the status this way guards against two common mistakes: assuming compounded means unregulated, and assuming it means FDA-approved. Neither is accurate. Compounded sermorelin sits in its own oversight framework, and the safest way to navigate it is to rely on a licensed prescriber and pharmacy who can explain exactly what you are receiving and why. That clarity, more than any label, signals a source you can trust, and one worth choosing over a louder alternative.

Frequently Asked Questions

Is sermorelin FDA approved today?

Sermorelin was FDA-approved in 1990 for diagnostic use and pediatric growth hormone deficiency, but the branded product was discontinued in 2008. The version most adults access now is a compounded preparation, which is not reviewed under the same FDA manufacturing process as an approved brand drug.

What does compounded sermorelin mean for me?

It means a licensed 503A pharmacy prepares the peptide patient-specifically under a prescription, overseen by state pharmacy boards rather than the brand-drug approval pathway. Preparation quality depends on the pharmacy, so verify state licensure and adherence to USP sterility and potency standards before use.

Is compounded sermorelin safe?

It carries a documented safety profile in the literature, but side effects and contraindications vary by preparation. Compounded products from licensed 503A pharmacies follow USP standards. Discuss your specific medical history with a prescribing provider, who can weigh warnings against your situation before you begin.

Does genetic testing change the regulatory picture?

No. Regulatory status is about the product, not your biology, and genetic testing does not alter it. The Precision Peptide Genetic Test reads pathway variants in FOXO3, IGF1, and KLOTHO that describe baseline biology, offering upstream context for a protocol conversation with your provider.

Keep reading across the PlexusDx Education Hub for more on peptides, metabolism, and the genetics beneath them. Return to the Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.